1. Home
  2. BAP vs RMD Comparison

BAP vs RMD Comparison

Compare BAP & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credicorp Ltd.

BAP

Credicorp Ltd.

HOLD

Current Price

$377.90

Market Cap

30.5B

Sector

Finance

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$218.27

Market Cap

34.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAP
RMD
Founded
1889
1989
Country
Peru
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.5B
34.0B
IPO Year
1997
1996

Fundamental Metrics

Financial Performance
Metric
BAP
RMD
Price
$377.90
$218.27
Analyst Decision
Buy
Buy
Analyst Count
5
10
Target Price
$309.60
$292.56
AVG Volume (30 Days)
298.1K
1.2M
Earning Date
05-14-2026
04-30-2026
Dividend Yield
3.46%
1.13%
EPS Growth
N/A
9.67
EPS
N/A
10.43
Revenue
N/A
$2,957,013,000.00
Revenue This Year
$23.26
$10.60
Revenue Next Year
$8.62
$7.41
P/E Ratio
$12.91
$21.09
Revenue Growth
N/A
13.44
52 Week Low
$230.45
$180.27
52 Week High
$423.17
$284.87

Technical Indicators

Market Signals
Indicator
BAP
RMD
Relative Strength Index (RSI) 48.99 43.94
Support Level $365.03 $218.39
Resistance Level $383.09 $222.43
Average True Range (ATR) 8.21 5.91
MACD 0.52 -2.63
Stochastic Oscillator 60.00 15.24

Price Performance

Historical Comparison
BAP
RMD

About BAP Credicorp Ltd.

Credicorp Ltd is a Peruvian financial services company. The company operates in four business lines, including Universal Banking, Insurance and Retirement, Microfinance, and Investment Banking and Asset Management. Its subsidiaries include Banco de Credito del Peru, Prima AFP, Credicorp Capital, and others. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

Share on Social Networks: